Cytotoxic T Lymphocyte Protein 4 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) – Pipeline Review, H2 2019’, provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology and Infectious Disease under development targeting Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)

– The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Abeome Corp

Aduro BioTech Inc

Agenus Inc

Akeso Biopharma Inc

Alligator Bioscience AB

AlphaMab Co Ltd

Alpine Immune Sciences Inc

Anaeropharma Science Inc

Apollomics Inc

AstraZeneca Plc

BeyondSpring Inc

Biocad

Biosortia Pharmaceuticals

BJ Bioscience Inc

Bristol-Myers Squibb Co

Cancure Ltd

Cellective BioTherapy Inc

Cold Genesys Inc

CStone Pharmaceuticals Co Ltd

DotBio Pte Ltd

Five Prime Therapeutics Inc

GigaGen Inc

Harbour BioMed

Hengenix Biotech Inc

Hualan Biological Engineering Inc

Immunocore Ltd

Immunwork Inc

Immutics Inc

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

JHL Biotech Inc

Jiangsu Alphamab Biopharmaceuticals Co Ltd

MacroGenics Inc

Merck & Co Inc

Momenta Pharmaceuticals Inc

Nanjing Jinsirui Biotechnology Co Ltd

OncoImmune Inc

Premier Biomedical Inc

Regeneron Pharmaceuticals Inc

Replimune Ltd

Serometrix LLC

Shanghai Henlius Biotech Inc

Shanghai Junshi Bioscience Co Ltd

Shanghai Mab Venture Biopharm Co Ltd

Sorrento Therapeutics Inc

Sound Biologics

Stcube Inc

Tikcro Technologies Ltd

Xencor Inc”

Table of Contents

Table of Contents

Table of Contents

Introduction

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Overview

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Therapeutics Development

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Therapeutics Assessment

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Companies Involved in Therapeutics Development

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drug Profiles

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Dormant Products

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Discontinued Products

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Product Development Milestones

Appendix

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..5), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Number of Products under Development by Companies, H2 2019 (Contd..2)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Products under Development by Companies, H2 2019 (Contd..11), H2 2019

Products under Development by Companies, H2 2019 (Contd..12), H2 2019

Products under Development by Companies, H2 2019 (Contd..13), H2 2019

Products under Development by Companies, H2 2019 (Contd..14), H2 2019

Products under Development by Companies, H2 2019 (Contd..15), H2 2019

Products under Development by Companies, H2 2019 (Contd..16), H2 2019

Products under Development by Companies, H2 2019 (Contd..17), H2 2019

Products under Development by Companies, H2 2019 (Contd..18), H2 2019

Products under Development by Companies, H2 2019 (Contd..19), H2 2019

Products under Development by Companies, H2 2019 (Contd..20), H2 2019

Products under Development by Companies, H2 2019 (Contd..21), H2 2019

Products under Development by Companies, H2 2019 (Contd..22), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Abeome Corp, H2 2019

Pipeline by Aduro BioTech Inc, H2 2019

Pipeline by Agenus Inc, H2 2019

Pipeline by Akeso Biopharma Inc, H2 2019

Pipeline by Alligator Bioscience AB, H2 2019

Pipeline by AlphaMab Co Ltd, H2 2019

Pipeline by Alpine Immune Sciences Inc, H2 2019

Pipeline by Anaeropharma Science Inc, H2 2019

Pipeline by Apollomics Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by BeyondSpring Inc, H2 2019

Pipeline by Biocad, H2 2019

Pipeline by Biosortia Pharmaceuticals, H2 2019

Pipeline by BJ Bioscience Inc, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by Cancure Ltd, H2 2019

Pipeline by Cellective BioTherapy Inc, H2 2019

Pipeline by Cold Genesys Inc, H2 2019

Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Pipeline by DotBio Pte Ltd, H2 2019

Pipeline by Five Prime Therapeutics Inc, H2 2019

Pipeline by GigaGen Inc, H2 2019

Pipeline by Harbour BioMed, H2 2019

Pipeline by Hengenix Biotech Inc, H2 2019

Pipeline by Hualan Biological Engineering Inc, H2 2019

Pipeline by Immunocore Ltd, H2 2019

Pipeline by Immunwork Inc, H2 2019

Pipeline by Immutics Inc, H2 2019

Pipeline by Innovent Biologics Inc, H2 2019

Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Pipeline by JHL Biotech Inc, H2 2019

Pipeline by Jiangsu Alphamab Biopharmaceuticals Co Ltd, H2 2019

Pipeline by MacroGenics Inc, H2 2019

Pipeline by Merck & Co Inc, H2 2019

Pipeline by Momenta Pharmaceuticals Inc, H2 2019

Pipeline by Nanjing Jinsirui Biotechnology Co Ltd, H2 2019

Pipeline by OncoImmune Inc, H2 2019

Pipeline by Premier Biomedical Inc, H2 2019

Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Pipeline by Replimune Ltd, H2 2019

Pipeline by Serometrix LLC, H2 2019

Pipeline by Shanghai Henlius Biotech Inc, H2 2019

Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019

Pipeline by Shanghai Mab Venture Biopharm Co Ltd, H2 2019

Pipeline by Sorrento Therapeutics Inc, H2 2019

Pipeline by Sound Biologics, H2 2019

Pipeline by Stcube Inc, H2 2019

Pipeline by Tikcro Technologies Ltd, H2 2019

Pipeline by Xencor Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019

Discontinued Products, H2 2019 (Contd..1), H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports